



Erratum

Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA_{1c} and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888–897

<https://doi.org/10.2337/dc23-er09>

Peter Rossing, Ellen Burgess, Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Luis M. Ruilope, Pieter Gillard, Richard J. Maclsaac, Julio Wainstein, Amer Joseph, Meike Brinker, Lothar Roessig, Charlie Scott, and George L. Bakris, on behalf of the FIDELIO-DKD Investigators

In Fig. 2 of the article cited above, due to a typographical error, the hazard ratio (HR) of the key secondary composite kidney outcome in the insulin at baseline subgroup was incorrectly reported as 0.74 (95% CI 0.59–0.94) instead of the correct HR of 0.77 (95% CI 0.62–0.94). In addition, the HRs of the secondary composite cardiovascular outcome were incorrectly reported as 0.88 (95% CI 0.71–1.09) for no insulin at baseline and 0.83 (95% CI 0.69–1.01) for insulin at baseline (*P* for interaction 0.70). The correct HRs for the secondary composite cardiovascular outcome are 0.95 (95% CI 0.74–1.23) for no insulin at baseline and 0.82 (95% CI 0.69–0.97) for insulin at baseline (*P* for interaction 0.33).

The authors apologize for the error.

The online version of the article (<https://doi.org/10.2337/dc21-1944>) has been updated to correct the error.